TherapeuticsMD
TXMD
155 hedge funds and large institutions have $1.17B invested in TherapeuticsMD in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 31 reducing their positions, and 14 closing their positions.
87% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 31
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
28% more call options, than puts
Call options by funds: $7.42M | Put options by funds: $5.8M
18% more capital invested
Capital invested by funds: $987M → $1.17B (+$182M)
8% more funds holding
Funds holding: 144 → 155 (+11)
0.07% more ownership
Funds ownership: 1.45% → 1.53% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Daruma Capital Management
New York
|
+$27.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.45M |
| 4 |
BlackRock
New York
|
+$9.42M |
| 5 |
PA
Perceptive Advisors
New York
|
+$9.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$3.63M |
| 2 |
Morgan Stanley
New York
|
-$1.51M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.46M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.43M |
| 5 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$1.19M |
TXMD Hedge Fund Activity: Q3 2018 in Review
155 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2018, worth a combined $1.17B — up 18% from $987M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TXMD positions and 14 closed out — a net gain of 12 holders — while 58 added to existing stakes and 31 trimmed.
The largest buyer was Daruma Capital Management, opening a new position worth an estimated $27.8M. The largest seller was D.E. Shaw & Co, cutting an estimated $3.63M.
- 155 institutional investors held TherapeuticsMD (TXMD) as of Q3 2018, up from 144 in Q2 2018.
- Funds reported $1.17B of TherapeuticsMD stock for Q3 2018, up 18% quarter-over-quarter.
- 26 funds opened new TherapeuticsMD positions in Q3 2018 and 14 closed out, a net change of +12 holders.
- The largest TherapeuticsMD buyer in Q3 2018 was Daruma Capital Management, an estimated $27.8M added.
- The largest TherapeuticsMD seller in Q3 2018 was D.E. Shaw & Co, an estimated $3.63M sold.
Based on aggregated 13F filings for Q3 2018.